Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades.If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 38% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $161,480 and 22, calls, for a total amount of $1,274,892.Predicted Price RangeAnalyzing the Volume and Open Interest in these con ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Black Diamond Therapeutics, Inc. is one of the twenty best biotech stocks. TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several models and price estimates throughout its biotechnology coverage, as well as an update to its 2026 Catalyst Tracker. Separately, on December 3, 2025, Black Dia ...

Company Overview - ImmunityBio, Inc. is a U.S. biotechnology company focused on developing next-generation immunotherapies and vaccines aimed at enhancing the natural immune system to combat cancers and infectious diseases [4] Financial Performance - Piper Sandler raised its price target on ImmunityBio, Inc. (IBRX) to $7 from $5, maintaining an Overweight rating [2] - U.S. ANKTIVA net sales surged by nearly 700% year over year, reaching $113 million in 2025, with projected revenue of $180 million in 2026 [2] Clinical Developments - ImmunityBio reported Phase 2 QUILT-3.078 results for recurrent GBM, showing that the longest survival was 12 months, with 19 out of 23 patients still alive [3] - The regimen demonstrated a reasonable safety profile, with preserved immunological competence and improved severe lymphopenia (ALC ≥1.4 ×10³/µL) [3] Future Prospects - There is potential for label expansion for ANKTIVA in 2027, contingent on positive data from the upcoming QUILT-2.005 study expected in Q4 2026 [2][3]

Core Insights - Arcturus Therapeutics Holdings Inc. (ARCT) is highlighted as a promising investment opportunity, particularly due to its undervaluation in the biotech sector [2][3]. Company Overview - Arcturus Therapeutics is a biotechnology company focused on developing mRNA-based vaccines and RNA therapeutics, utilizing proprietary delivery technologies [4]. - The company's pipeline addresses infectious diseases such as COVID-19 and influenza, as well as rare liver and respiratory disorders [4]. Market Analysis - Roth Capital initiated coverage of ARCT with a Buy rating and a price target of $20, indicating that the company's mid-stage programs have significant clinical activity and peak sales potential exceeding $1 billion [2]. - Roth noted that ARCT shares are trading near their cash value, implying a 0% chance of success for its pipeline assets, suggesting that the stock may be mispriced in the rare disease sector [2]. - Citigroup recently lowered its price target for ARCT from $9 to $7 while maintaining a Neutral rating, emphasizing opportunities in SMID-cap biotech for 2026, especially for companies nearing commercialization [3].

Core Insights - Lexeo Therapeutics, Inc. (LXEO) is currently ranked sixteenth in a list of the 20 Best Biotech Stocks Under $20 to Buy Now, indicating its potential as an investment opportunity [1] - H.C. Wainwright analyst Mitchell Kapoor has lowered the price target for LXEO from $13 to $10 while maintaining a Buy rating, suggesting that the market remains skeptical about LXEO's recent PKP2 findings [1][2] - The preliminary results from the HEROIC-PKP2 Phase I/II trial of LX2020, a gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, showed no clinically significant complement activation and that LX2020 was generally well tolerated [2] Company Overview - Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing innovative gene and RNA therapies aimed at addressing the underlying causes of cardiovascular diseases [3] - The company is advancing candidates for conditions such as Friedreich's ataxia and arrhythmogenic cardiomyopathy, with the goal of improving long-term heart health outcomes [3] Trial Results - In the HEROIC-PKP2 trial, PKP2 protein levels increased in a dose-dependent manner, averaging 93% in the low-dose group and 162% in the high-dose group, indicating a positive response to treatment [2] - The trial also noted improvements or stabilization in arrhythmia features, such as premature ventricular contractions and non-sustained ventricular tachycardia [2]

Company Overview - 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage biotechnology company focused on developing targeted gene therapies using its proprietary Therapeutic Vector Evolution platform [4]. Clinical Developments - The company is conducting the 4FRONT Phase 3 investigations of 4D-150 for Wet AMD, involving 480 patients in each phase, with 381 participants already randomized for 4FRONT-1. Global enrollment for 4FRONT-2 is expected to be completed by the second half of 2026 [3]. - A global Phase 3 trial for diabetic macular edema is scheduled for Q3 2026, and results from the 2-year SPECTRA Phase 1/2 trial are anticipated in the second half of 2026. Additionally, updates on the Phase 2 4D-710 program for cystic fibrosis are expected in the same timeframe [3]. Market Position and Analyst Ratings - Barclays initiated coverage of FDMT with an Overweight rating and a price target of $33, citing solid fundamentals in the biotech industry, the undervaluation of several companies, and anticipated tailwinds from mergers and acquisitions [2][3]. - The report highlights pricing relief as a potential upside catalyst for FDMT and the broader biotech sector [2][3].

Core Insights - OSR Holdings, Inc. emphasizes its strong fundamentals and commitment to long-term value creation despite market volatility and uncertainty [2][7] - The company is making significant progress in licensing its lead asset, VXM01, through a binding term sheet with BCM Europe AG, which is seen as a validation of its biotech strategy [3][8] - Ongoing strategic discussions for a merger between its medical device subsidiaries, RMC and Woori IO, are encouraged by recent regulatory clarity from the U.S. FDA, enhancing commercialization strategies [4][5] Licensing and Development - The licensing transaction for VXM01 could yield up to USD 815 million in development, regulatory, and commercial milestones, with an upfront consideration of USD 30 million [8] - The transaction structure is progressing in line with previously disclosed economic frameworks, indicating a positive outlook for the asset [3] Medical Device Strategy - Woori IO is positioned to pursue a dual-track commercialization strategy for consumer wearable products, which can be marketed independently of medical-device regulatory approvals [9] - The merger with RMC is expected to create a strong foundation for growth, with plans for a potential listing on the KOSDAQ market, which has recently reached a 25-year high [6] Future Outlook - OSR Holdings is focused on disciplined capital allocation and strategic partnerships to enhance its portfolio of healthcare technologies, maintaining its mission despite short-term market dynamics [7][10] - The management is actively engaging with regulators and partners to meet Nasdaq listing requirements while advancing transactions that could unlock substantial shareholder value [10]

Company Overview - Legend Biotech Corporation (NASDAQ: LEGN) is a global biotechnology company focused on developing and commercializing advanced cell therapies, particularly CAR-T treatments for cancer, such as CARVYKTI for multiple myeloma [3]. Sales Performance - In Q4, Carvykti sales reached $555 million, which fell short of the consensus estimate of $582 million. This sales miss has been attributed to holiday seasonality and sluggish demand influenced by toxicity concerns and increasing competition [2]. Analyst Ratings and Price Targets - H.C. Wainwright lowered the price target for LEGN from $60 to $50 but maintained a Buy rating, viewing the recent pullback as a buying opportunity due to Carvykti's curative potential [1]. - Conversely, TD Cowen downgraded Legend Biotech from Buy to Hold and reduced the price target from $62 to $21, citing concerns over demand and competition affecting sales [2].

Group 1 - Intellia Therapeutics, Inc. (NTLA) is ranked seventh in a list of the 20 Best Biotech Stocks Under $20 to Buy Now [1] - Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating, following the FDA's lifting of the clinical hold on the Nex-z hATTR-PN trial [1][2] - H.C. Wainwright analyst increased the price target on NTLA to $25 from $15 and maintained a Buy rating, noting that the FDA's decision indicates manageable risks for Nex-Z and raised the probability of approval for Nex-Z to 35% from 25% [2] Group 2 - Intellia Therapeutics is a clinical-stage biotechnology company focused on CRISPR-based gene editing therapies for serious genetic diseases, utilizing proprietary in vivo and ex vivo platforms [3] - The company is advancing multiple programs aimed at providing durable, curative solutions and expanding the potential of gene editing [3]

Group 1: Company Overview - Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biotechnology company focused on developing novel immunotherapies that activate both innate and adaptive immune responses to treat cancer [5] - The company's pipeline emphasizes engineered cytokine and receptor-targeted therapies aimed at enhancing antitumor activity while improving safety [5] Group 2: Recent Developments - On January 22, Janux Therapeutics announced an exclusive worldwide license and collaboration agreement with Bristol Myers (NYSE: BMY) to develop a novel tumor-activated therapy targeting a validated solid tumor antigen [3] - Under the agreement, Bristol Myers will hold the Investigational New Drug (IND) application and oversee global development and commercialization once Janux completes preclinical development [3] Group 3: Financial and Market Position - Clear Street downgraded Janux Therapeutics from Buy to Hold and reduced the price target from $32 to $12, citing a lack of clear durability signals from JANX007 and the absence of new data from JANX008 as significant risks [2] - The firm also highlighted rising competitive pressure and an undefined path for JANX007, which increases execution risk [2] - Janux is eligible for up to $50 million in upfront and near-term milestones, along with potential later development, regulatory, and commercial milestones totaling over $800 million [4]